"People are too impatient with the current launch status of biosimilars," Ko said in an interview with BioPharma Dive this month. "Market shaping takes time."
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,